Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients

Qasim Kadhim Farhood1
Sinan Mohammad Twfeeq2
1College of Medicine, Babylon University, Babylon; 2Al-Jumhori teaching hospital, Mosul, Iraq

Background: This study examined the changes in short-term intraocular pressure (IOP) in a prospective series of patients undergoing intravitreal bevacizumab injection. The aim was to evaluate the frequency and predictive factors related to intraocular pressure (IOP) elevation in patients receiving intravitreal bevacizumab.

Patients and methods: This study included 52 patients with diabetic retinopathy between 28 to 75 years of age with a mean age of 51 years; 30 (58%) were females, and 22 (42%) were males. All patients received bevacizumab (1.25 mg/0.05 mL) injected intravitreally in a standard fashion between May 2012 to February 2013 in the AL-Jumhoury teaching hospital. IOP was measured at baseline, 5, 10, and 30 minutes after injection using Goldman applanation tonometry.

Statistics: Data were analyzed using the SPSS v.12.0 for windows. Basic, demographic, and clinical data were analyzed using means, proportions, and appropriate 95% confidence intervals (CIs).

Results: Most patients (85%) were diagnosed with proliferative diabetic retinopathy, while 15% presented with diabetic macular edema. The mean IOP values at baseline, 5, 10, and 30 minutes after injection were 14.0 mmHg (95% CI 13.4–14.7), 36.1 mmHg (95% CI 33.5–38.6), 25.7 mmHg (95% CI 23.8–27.5), and 15.5 mmHg (95% CI 12.4–16.5), respectively. Regression analysis showed a trend toward phakic patients having higher IOP at 30 minutes.

Conclusion: Intravitreal injection of bevacizumab is safe with respect to short-term IOP changes, as almost all IOP returned to a safe range (<25 mmHg) within 30 minutes. Elevated IOP 30 minutes after injection only occurs rarely, so routine prophylactic use of anti-glaucoma medication is not indicated.

Keywords: intravitreal injection, bevacizumab, intraocular pressure, Goldmann applanation tonometry

Introduction
Bevacizumab (Avastin® F. Hoffmann-La Roche Ltd., Basel, Switzerland) is a humanized monoclonal antibody that inhibits endothelial growth factor, and is rapidly becoming one of the leading treatments for neovascular age-related macular degeneration (AMD).1 There is growing evidence of the benefits of bevacizumab for treating other ocular diseases associated with neovascularization, such as diabetic retinopathy.2 Also, bevacizumab has been reported to cause rapid regression of anterior segment neovascularization in eyes with neovascular glaucoma.3

Intravitreal vascular endothelial growth factor (VEGF) antagonists are now being used by ophthalmologists to treat various ischemic retinal disorders4 and to improve vision in patients with macular edema due to diabetic retinopathy and vein occlusion.5 The largest
collection of data concerning the safety of bevacizumab was compiled by the International Intravitreal Bevacizumab Safety Survey,\(^1\) which reported on complications, such as endophthalmitis, cataract progression, subretinal hemorrhages, and retinal tears. However, as that report relied on voluntary reporting to ascertain complication rates, underestimation of these rates seems quite possible. Furthermore, the role of intraocular hypertension was not studied quantitatively.

Numerous published reports highlight the potential for a significant rise in intraocular pressure (IOP) following intravitreal injections in general.\(^6\)\(^7\) An acute rise in IOP has been shown in animal models to block axonal transport to the optic nerve head; in addition, a higher rise in IOP is associated with more severe damage.\(^8\) An acute rise in IOP has also been shown to decrease juxtapapillary retinal and optic nerve head blood flow proportionally to the quantitative rise in IOP.\(^10\)

Three studies have investigated the short-term changes in IOP following intravitreal injection of triamcinolone acetonide (TA).\(^5\)\(^6\)\(^8\) A study by Benz et al\(^9\) showed that the IOP normalized in most patients 30 minutes after injection, but 10% of patients who did not have vitreous reflux after injection had an IOP greater than 25 mmHg at 30 minutes. The mechanism for the short-term IOP rise immediately after intravitreal injection of TA was thought to be a result of the increase in volume of the vitreous cavity after injection. As the intravitreal use of bevacizumab is growing exponentially, the safety of this procedure is of fundamental importance. Given the potential for significant IOP elevation in the immediate post-injection period, we investigated the changes in IOP following a 0.05 mL intravitreal bevacizumab injection in order to outline more clearly the safety of this novel treatment modality.

**Patients and methods**

A prospective case series of 52 patients undergoing intravitreal injection of bevacizumab at the ophthalmology department, Al-Jumhori teaching hospital, Mosul, Iraq, from May 2012 to February 2013 was included in this study. Patient ages ranged from 28 to 75 years (mean 51.5; Table 1). To maximize generalizability, exclusion criteria were kept to a minimum, and included previous ocular surgeries or intravitreal injections of corticosteroid within the previous 3 months. Ethics approval was obtained and informed consent was attained from each patient in the study.

**Technique**

Intravitreal injections were given using similar techniques. Demographic and clinical data (Table 1) were collected through patient interview and chart review. Visual acuity and IOP values were obtained at baseline. Patients were prepared and draped in a standard fashion and positioned supine for the procedure. A solution of 10% povidone-iodine was used for sterilization; a wire lid speculum was applied for lid control, and before injection, topical antibiotic drops (5% povidone-iodine solution and topical 0.5% proparacaine drops) were instilled into the conjunctiva. The intravitreal bevacizumab injection was prepared by drawing-up approximately 0.1 mL of bevacizumab (2.50 mg/0.1 mL) into a 1.0 mL tuberculin syringe. The excess was removed, and the remainder 0.05 mL (1.25 mg) was injected with a 30-gauge needle through the inferotemporal or inferonasal pars plana at 3.0 mm or 3.5 mm posterior to the limbus if the patient was pseudophakic or phakic, respectively. The needle was inserted approximately 1.0 cm into the globe, and the injection was performed. After injection, a sterile cotton swab was placed on the injection site to prevent reflux of the medicine, and one drop of topical moxifloxacin was instilled (Vigamox; Alcon Laboratories Inc., Fort Worth, TX, USA). Thereafter, prophylactic topical moxifloxacin drops were continued for a few days.

Patients were examined by slit-lamp, and an IOP measurement was performed at 5, 10, and 30 minutes after injection using Goldmann applanation tonometry. If the

<table>
<thead>
<tr>
<th>Variable</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>30 (57.6)</td>
</tr>
<tr>
<td>Male</td>
<td>22 (42.4)</td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
</tr>
<tr>
<td>28–49</td>
<td>21 (40.3)</td>
</tr>
<tr>
<td>50–59</td>
<td>20 (38.4)</td>
</tr>
<tr>
<td>60–69</td>
<td>7 (13.4)</td>
</tr>
<tr>
<td>70+</td>
<td>4 (7.7)</td>
</tr>
<tr>
<td>Glaucma</td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>16 (15.4)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
</tr>
<tr>
<td>Proliferative diabetic retinopathy</td>
<td>44 (84.6)</td>
</tr>
<tr>
<td>Diabetic macular edema</td>
<td>8 (15.4)</td>
</tr>
<tr>
<td>Injection number</td>
<td></td>
</tr>
<tr>
<td>One</td>
<td>16 (30.7)</td>
</tr>
<tr>
<td>Two</td>
<td>25 (48.0)</td>
</tr>
<tr>
<td>Three</td>
<td>10 (19.2)</td>
</tr>
<tr>
<td>Four</td>
<td>1 (1.9)</td>
</tr>
<tr>
<td>Eye</td>
<td></td>
</tr>
<tr>
<td>OS</td>
<td>30 (57.6)</td>
</tr>
<tr>
<td>OD</td>
<td>22 (42.4)</td>
</tr>
<tr>
<td>Lens status</td>
<td></td>
</tr>
<tr>
<td>Phakic</td>
<td>29 (55.7)</td>
</tr>
<tr>
<td>Pseudophakic</td>
<td>23 (44.3)</td>
</tr>
</tbody>
</table>

**Abbreviations:** OS, oculus sinister (left eye); OD, oculus dexter (right eye).
IOP was ≥25 mmHg after 30 minutes then the patient was observed for another 1.5 hours and if the IOP was still elevated anti-glaucoma medication was prescribed.

To investigate the reliability of IOP measurements between the two observers, an interobserver reliability study was performed. In a random group of patients not involved in the study and with normal intraocular pressure, IOP was measured by both of the observers consecutively. Both observers were blind to any previous IOP measurements in the patient chart, and the second observer was blind to the IOP measurement taken by the first observer. An intraclass correlation coefficient was used to assess inter-rater reliability of IOP measurements between the two examiners.

Data were analyzed using the Statistical Package for the Social Sciences v. 12.0 for Windows (SPSS Inc., Chicago, IL, USA). Basic demographic and clinical data were analyzed using means, proportions, and appropriate 95% confidence intervals (CIs). The main outcome measure was the proportion of patients with an IOP above 24 mmHg at 30 minutes after injection. A secondary outcome measure was the proportion of patients with an IOP ≥5 mmHg above baseline at 30 minutes after injection. Multivariate logistic regression analysis with backward selection (exclusion of P=0.10) was used to simultaneously investigate factors associated with increased IOP after 30 minutes.

### Results

Fifty-two diabetic retinopathy patients were included in this study, 30 (57.6%) of whom were female and 22 (42.4%) were male, with a mean age of 51 (standard deviation 10.33) years. Most patients (84.6%) were receiving intravitreal bevacizumab injections for neovascularization due to diabetic retinopathy. Table 1 shows basic demographic and clinical data of the studied patients.

We sampled 41 patients randomly for our interobserver reliability study. IOP measurements were within 3 mmHg in 90.2% of cases. The intraclass correlation coefficient between observers was 0.87 (95% CI 0.77–0.93).

For all studied patients, the mean IOP values (Table 2 and Figure 1) at baseline, 5, 10, and 30 minutes after injection were 14.0 mmHg (95% CI 13.4–14.7), 36.1 mmHg (95% CI 33.5–38.6), 25.7 mmHg (95% CI 23.8–27.5), and 15.5 mmHg (95% CI 12.4–16.51), respectively. Patients with a history of glaucoma (n=16) had higher baseline IOP (P=0.041).

Table 2 shows the range of IOP values at baseline and at the three post-injection intervals. IOP increased sharply 5 minutes after injection (P<0.0005); four patients (7.69%) had an IOP 50–59 mmHg and one patient had an IOP over 60 mmHg. Over the next 30 minutes, IOP returned back to normal; however, at 5 and 30 minutes after injection, the mean IOP remained statistically significantly above baseline (P<0.0005 and P<0.02, respectively). Thirty minutes post-injection, nine patients (17.3%) had IOPs 5 mmHg greater than baseline values, but for only two patients (3.84%) the IOP was higher than 25 mmHg after 30 minutes. The IOP of one of those patients (with a 30 minute value of 28 mmHg) returned to under 25 mmHg within 2 hours and did not require initiation of anti-glaucoma medication. The other patient, whose IOP at 30 minutes was 45 mmHg and still elevated after 2 hours, was put on a trend toward phakic patients having higher IOP at 30 minutes after injection. Since only a small proportion of patients had an IOP of ≥25 mmHg at 30 minutes (primary outcome), we used the secondary outcome measure (IOP ≥5 mmHg above baseline) as our dependent variable in the regression analysis. Regression analysis showed a trend toward those patients having higher IOP at 30 minutes after injection. Since only a small proportion of patients had an IOP of ≥25 mmHg at 30 minutes, we used the secondary outcome measure (IOP ≥5 mmHg above baseline) as our dependent variable in the regression analysis. Regression analysis showed a trend toward phakic patients having higher IOP at 30 minutes (odds ratio =3.2; P=0.089). The following demographic and clinical variables were not statistically significant in our model: sex, age, history of glaucoma, diagnosis requiring intravitreal bevacizumab injection, previous injections, and eye (OS [left eye] or OD [right eye]).

### Discussion

Intravitreal injection has become an increasingly common intervention for the treatment of retinal disease. Intravitreal bevacizumab is being positioned as a major treatment...
modality for exudative AMD, which is the leading cause of new blindness in North America.\(^1\)

Our study showed that a 0.05 mL intravitreal bevacizumab injection has an excellent safety profile with respect to sustained short-term IOP changes. Although there was a statistically significant higher IOP at 30 minutes after injection when compared with baseline, this difference (1.4 mmHg) was not clinically significant. The vast majority (96.1%) of patients had an IOP of less than 25 mmHg after 30 minutes. However, our study showed that IOP rises substantially in some patients immediately after injection, but it rapidly normalizes. Transient increases in IOP are not uncommon with the addition of fluid into the vitreous cavity. There have been several published reports demonstrating short-term, transient increases in IOP after injection of intravitreal anti-VEGF agents, which were shown to return to <25 mmHg within 30 to 60 minutes without IOP-lowering therapy.\(^{11-14}\) These studies suggested increases in IOP tend to be higher in phakic patients.\(^{11}\) Frenkel et al\(^{15}\) concluded that intraocular pressure spikes after intravitreal injection of anti-VEGF agents are common and in most cases transient, so routine prophylactic use of IOP lowering medications is not necessary. Therefore, frequent IOP monitoring for normalization after intravitreal injections may not be necessary on the day of injection, as only 7 patients (13.45%) experienced an IOP spike above 50 mmHg. This likely induces ocular perfusion pressures below the auto-regulatory range of optic nerve head blood flow.\(^{16}\) Moreover, acute deformations in the contour of the lamina cribrosa also occur at these IOPs.\(^{17,18}\) The long-term consequences of these transient events are unknown. However, the potential for negative sequelae should be considered, especially in patients with advanced glaucomatous optic neuropathy. A pre-injection anterior chamber paracentesis as prophylaxis may be considered for these patients.

Two patients developed high IOP after intravitreal injection: the IOP normalized over 1.5 hours for one patient, while the other one required a short course of IOP-lowering medications. The latter patient was male, relatively young (<50 years), had a 30-minute IOP of 45 mmHg, and was being treated for diabetic macular edema. He did not have previous glaucoma but had received an intravitreal injection of a corticosteroid within the previous year; therefore, it is possible that this patient sustained some damage to the trabecular meshwork as a result of the previous steroid injection and was consequently unable to adequately clear the additional volume of fluid from the injection. Our sample was too small to study this question adequately, but future research into IOP change after intravitreal bevacizumab injection in patients with previous corticosteroid injection may be helpful.

Benz et al\(^{16}\) studied short-term IOP changes after injection of 0.1 mL intravitreal TA. They found that 7.1% of patients had an IOP greater than 25 mmHg at 30 minutes after injection and postulated that the IOP rise after injection may be mechanical, as a result of the 2.5% increase in vitreous volume. In our study, two patients (3.84%) had IOP values over 25 mmHg after 30 minutes. The most obvious reason for this difference compared to the previous study is that we injected less medication (0.05 mL versus 0.1 mL) into the vitreous cavity. In addition, bevacizumab is not known to cause IOP increases in the long-term, whereas corticosteroids have a known long-term risk of ocular hypertension linked to corticosteroid-dependent mechanical and biochemical changes to the trabecular meshwork\(^{19,20}\) resulting in increased aqueous outflow resistance, owing to an accumulation of extracellular matrix material in the trabecular meshwork.\(^{20}\)
Many studies have investigated short-term IOP changes after intravitreal administration of TA. Our study is prospective and has a relatively larger sample size compared to other similar safety studies. We deliberately used minimal exclusion criteria in order to simulate the safety of this treatment modality in the real world; consequently, this can be considered a strength of the study.

In addition, we demonstrated excellent inter-rater reliability with respect to IOP measurement. One weakness of our study was not quantifying medication refux at the time of injection. This has been done in the past when short-term IOP changes after intravitreal injection of corticosteroids have been studied and might have enabled better prediction for patients with immediate IOP pressure spikes. However, vitreous reflux is a subjective measure and is especially difficult to quantify with intravitreal bevacizumab injections since the medication is clear. This is different from the reflux of intravitreal TA, which has a milky-white appearance and would be easier to quantify. Therefore, it is uncertain whether attempting to quantify vitreous reflux of the bevacizumab would have added reliable data to our study.

**Conclusion**

Intravitreal bevacizumab injections have an excellent safety profile with respect to short-term IOP changes. Extreme transient IOP elevations may occur in some patients. Clinicians should consider checking IOP after intravitreal bevacizumab injection as a precaution especially in patients with glaucoma.

Intraocular pressure spikes after intravitreal injections of bevacizumab are common and in the majority of cases are transient so routine prophylactic use of anti-glaucoma medications before or after injection is ineffective in preventing IOP elevations. Anti-glaucoma medications should be prescribed when IOP values exceed 25 mmHg 2 hours after injection.

**Acknowledgments**

We thank Biometricians for statistical analysis support.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**
